drugset / Trial / NCT00203957
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm the long term tolerability and safety of oral 20 or 40 mg/d doses of Istradefylline.
Timeline
- Start
- 2005-03
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 20 mg | Oral |
| Subject | Istradefylline | Small molecule | 40 mg | Oral |